A Clinical Study to Assess the Safety and Effectiveness of Test Products in Mild to Moderate Atopic Dermatitis (AD) Patients.

A study testing Treatment Cream in people with Atopic Dermatitis, run by NovoBliss Research Pvt Ltd at 1 site in India.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

This is an exploratory, proof-of-concept, double-blind, placebo-controlled, randomized, comparative, interventional, prospective, safety in-use tolerability and efficacy study of test products in patients with mild to moderate Atopic Dermatitis. Read more about this study

Who is it for?: Ages 6 to 65 years
Conditions the study is for: Atopic Dermatitis
What is being tested?: Treatment Cream
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 44 participants
Where: 1 siteIndia
Study dates: 20 Nov 2024to 20 Feb 2025
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 6 to 65 years
All sexes
No healthy volunteers
Child, Adult, Older adult

Who may be able to join

1) Age: For children: 6 years and above (both inclusive) at the time of parental consent/assent and For Adults: 18 to 65 years (both inclusive) at the time of consent.
2) Sex: Healthy children (male or female) and adults (males and non-pregnant/non-lactating females) with mild to moderate atopic dermatitis.
3) Subject's with TEWL >15 g/m²/h and Moisture level <20% at the time of screening.
4) Subject's with mild to moderate Atopic Dermatitis determined by Eczema Area and Severity Index (EASI) score with moderate erythema (redness: score 2) and mild scratch mark (scratching: score 1) will be enrolled into the study.
5) Subject is diagnosed with mild to moderate atopic dermatitis with at least 1 active lesion that are accessible for instrumental measurements.
6) Females of childbearing potential should have a negative urine pregnancy test at the time of screening visit.

Show all 23Show fewer

7) Subjects (adults and children) are generally in good general health as determined from a recent medical history, except for the atopic dermatitis.
8) If subjects (adults and children) are using or taking any prescription or over the counter (OTC) medications prescribed by their physicians, they must be taking the medication for at least 4 weeks.
9) Subject's and child's legal parent or guardian must agree to use the same brands and agree not to switch brands or variants of any skin care products during the study period.
10) Subject's and child's legal parent or guardian must agree to limit the sun exposure to affected areas such as arms, legs covered during prolonged sun exposure.
11) Subject's and child's legal parent or guardian must agree to dress the subjects in loose clothing to allow easy exposure to the entire body during study visits and throughout study duration of 60 days.
12) Subjects and Legal parent or guardian must avoid allowing the subject a hot or cold beverage within one hour of their scheduled visits and for the duration of all clinic visits, warm beverages are allowed.
13) Subjects and Legal parent or guardian must avoid allowing subject to swim or play in chlorinated water during study period.
14) Subjects are not allowed to participate in any other study until this study is complete.
15) Subjects and child's legal parent or guardian must be willing and able to follow the study directions and to return for all specified visits with the subject.
16) Subjects and Child's legal parent or guardian must be willing to stop using all of the subject's normal body lotions for the duration of the study (8 weeks) and to use the provided test daily lotion as directed.
17) Subjects and Child's legal parent or guardian must agree to record each use of the test products in the subject's diary card on daily basis.
18) Subjects and Child's legal parent or guardian must agree to record medication use during the study.
19) Subject's and child's legal parent or guardian must read, sign, and receive a copy of Informed Consent/Parental Informed Consent prior to initiate of study procedures.
20) Having childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
21) Subjects willing to give written informed consent and are willing to come for regular follow up.
22) Subjects have not participated in a similar investigation in the past three months.
23) Subjects willing to use test product throughout the study period.

Who cannot join

Subjects with AD on the scalp (with hair), palms, and soles.
Subjects with active skin infections.
Subjects with other dermatologic diseases besides AD whose presence or treatments could interfere with the assessment of disease (eg, Psoriasis).
Subjects who used systemic immunosuppressants within 4 weeks, topical steroids or immunomodulators within 1 week, moisturizers within 12 hours before evaluation.
Subjects with milk allergies.
Change in current prescriptions (within 4 weeks of screening) or new and/or additional prescriptions for the skin condition (within 4 weeks of screening) or during the study.

Show all 15Show fewer

The subject has a known allergy or sensitivity to soaps, lotions, detergents, detanglers or fragrances.
The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject.
The subject has any of the conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results.
Subjects having diabetes, hepatitis, epilepsy, thyroid or have or had any kind of cancer.
The subject is currently taking or has taken any medication, which the Investigator believes may influence the interpretation of the data, such as 3 or more dosage or 3 or more days of anti-inflammatories (within 1 week of study enrolment) or anti-histamines and steroids.
The subject must not have participated in a clinical study within 4 weeks prior to the screening visit of this study.
Any other condition which could warrant exclusion from the study, as per the dermatologist's/investigator's discretion.
Pregnant or breastfeeding or planning to become pregnant during the study period.
History of chronic illness which may influence the cutaneous state.

Trial locations and contacts

1 site in 1 country.

India1 site

NovoBliss Research Pvt Ltd
Ahmedabad, Gujarat, 382481

Other trials in India

About this study

Official title: An Exploratory, Proof-of-Concept, Double-Blind, Placebo-Controlled, Randomized, Comparative, Interventional, Prospective, Safety In-Use Tolerability and Efficacy Study of Test Products in Patients With Mild to Moderate Atopic Dermatitis (AD).

Read the detailed description

A total of 44 patients with mild to moderate Atopic Dermatitis for at least 6 months will be enrolled in the study to complete 40 patients having confirmed diagnosis of atopic dermatitis.

Subjects will be called on the telephone by the recruiting department. Subjects will be pre-screened by the screening department of NovoBliss Research.

Following ethics committee approval and written informed consent or assent, eligible participants underwent the protocol-specified screening assessments, including instrumental measurements and standardized photography.

The subjects will be instructed to visit the facility as per the below visits. Visit 01 (Day 01): Screening, Randomization, Baseline Evaluation, Post application evaluation Visit 02 (Day 15 ±2 Days): Test products usage, Telephonic Follow-up Visit 03 (Day 30 ±2 Days): Test products usage, Evaluations. Visit 04 (Day 60 ±2 Days): Final Evaluation, End of Study.

Conditions: Atopic Dermatitis
Being tested: Treatment Cream, Placebo
Medical subject headings: Dermatitis, Atopic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Treatment CreamOther
Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.
Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical
PlaceboOther
Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.
Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical

Study groups in NCT06687512
Study group	Role	What they receive
Treatment Cream	Experimental	Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups. Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical Receives: Other: Treatment Cream
Placebo Cream	Placebo comparator	Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups. Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

To evaluate the effectiveness of the test products in terms of change in Dry Skin/Ichthyosis Area and Severity Index (DASI)
Scale indicates 0-4 categorical scale (0: absent, 1: slight, 2: moderate, 3: severe, 4: extreme). improvement in DASI score will be evaluated.
Measured: baseline before usage on Day 01 and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness of the test products in terms of changes in SCORAD severity scoring,
Total SCORAD index is 103. Higher scores indicating greater severity. 0-3 description applies only to individual intensity components (0 indicates none, 1 indicates mild intensity, 2 indicates moderate intensity, and 3 indicates severe intensity). Improvement in SCORAD score
Measured: before usage of the test products on Day 01 and after usage of test products at 30 mins on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in Eczema Area and Severity Index
The total maximum score for the EASI is 72. Scoring Scale indicates none (0), mild (1), moderate (2) and severe (3). 0-3 description applies only to individual signs. Improvement in EASI score will be evalauted.
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual assessment of post inflammatory hyperpigmentation.
Scoring scale indicates a 0-4 categorical scale (0: absent, 1: slight, 2: mild, 3: moderate, 4: maximum). Improvement in PIHASI score.
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).

Secondary outcomes (12)

To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin scaliness
Scoring scale indicates 0: absent and 4: extreme. % of participants reported
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment including roughness
Scoring scale indicates 0: absent and 4: extreme. % of participants reported
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin redness
Scoring scale indicates 0: absent and 4: extreme. % of participants reported
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin itchiness
Scoring scale indicates 0: absent and 4: Severe. % of participants reported
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin dryness
Scoring scale indicates 0: absent and 4: Severe. % of participants reported
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin smoothness
Scoring scale indicates 0: absent and 4: Severe. % of participants reported
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in Visual Analogue Scale for Itching
Scale where 0 indicates No itching and 100 indicates most severe itching imaginable
Measured: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in skin hydration
Change in skin hydration (a.u.) by Corneometer CM 825
Measured: baseline before usage and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness of the test products in terms of changes in skin barrier function
Change in skin barrier function (g/m²/h) using TEWAMeter TM Hex
Measured: before usage and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness of the test products in terms of changes in skin topography
Change in skin topography (a.u.) by VISIOSCAN VC 20
Measured: before usage and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness impact of the test products in the shift of skin microbiome by collecting skin swab
Change in shift of skin microbiome by collection skin swab.
Measured: before usage on Day 01 and after usage on Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness of the test products in terms of changes in product perception questionnaire
5-point Likert Scale indicates 1: Not at all and 5: to large extent
Measured: before usage and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

20 Nov 202420 Feb 2025

First posted13 Nov 2024
Study start20 Nov 2024
Primary completion20 Feb 2025
Study completion20 Feb 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Atopic DermatitisStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 44 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06687512
Sponsor's protocol ID: NB240037-BM
Status last verified: Aug 2026
First submitted: 19 Oct 2024
Last updated: 10 Aug 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis

All Atopic Dermatitis trials

Study at a glance

From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: An Exploratory, Proof-of-Concept, Double-Blind, Placebo-Controlled, Randomized, Comparative, Interventional, Prospective, Safety In-Use Tolerability and Efficacy Study of Test Products in Patients With Mild to Moderate Atopic Dermatitis (AD).
ClinicalTrials.gov ID: NCT06687512
Acronym / sponsor ID: NB240037-BM
Conditions: Atopic Dermatitis
Study type: Interventional
Recruitment status: Completed
Enrolment: 44 participants (actual)
Lead sponsor: NovoBliss Research Pvt LtdUniversity, hospital or other
Collaborators: Blossom Microbiotics LLC
Study start: 20 Nov 2024 (actual)
Primary completion: 20 Feb 2025 (actual)
Study completion: 20 Feb 2025 (actual)
First posted: 13 Nov 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

A total of 44 patients with mild to moderate Atopic Dermatitis for at least 6 months will be enrolled in the study to complete 40 patients having confirmed diagnosis of atopic dermatitis.

Subjects will be called on the telephone by the recruiting department. Subjects will be pre-screened by the screening department of NovoBliss Research.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 2

Arm	Type	Receives
Treatment Cream	Experimental	Other: Treatment CreamMode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups. Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical
Placebo Cream	Placebo comparator	Other: PlaceboMode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups. Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical

Who may qualify

Ages: 6 to 65 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Child, Adult, Older adult

Key inclusion criteria (23 listed)

1) Age: For children: 6 years and above (both inclusive) at the time of parental consent/assent and For Adults: 18 to 65 years (both inclusive) at the time of consent.
2) Sex: Healthy children (male or female) and adults (males and non-pregnant/non-lactating females) with mild to moderate atopic dermatitis.
3) Subject's with TEWL >15 g/m²/h and Moisture level <20% at the time of screening.
4) Subject's with mild to moderate Atopic Dermatitis determined by Eczema Area and Severity Index (EASI) score with moderate erythema (redness: score 2) and mild scratch mark (scratching: score 1) will be enrolled into the study.
5) Subject is diagnosed with mild to moderate atopic dermatitis with at least 1 active lesion that are accessible for instrumental measurements.

Key exclusion criteria (15 listed)

Subjects with AD on the scalp (with hair), palms, and soles.
Subjects with active skin infections.
Subjects with other dermatologic diseases besides AD whose presence or treatments could interfere with the assessment of disease (eg, Psoriasis).
Subjects who used systemic immunosuppressants within 4 weeks, topical steroids or immunomodulators within 1 week, moisturizers within 12 hours before evaluation.
Subjects with milk allergies.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Treatment CreamMode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups. Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical	Other	Treatment Cream
PlaceboMode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups. Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical	Other	Placebo Cream

Primary outcome

To evaluate the effectiveness of the test products in terms of change in Dry Skin/Ichthyosis Area and Severity Index (DASI)
Time frame: baseline before usage on Day 01 and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)
Scale indicates 0-4 categorical scale (0: absent, 1: slight, 2: moderate, 3: severe, 4: extreme). improvement in DASI score will be evaluated.
To evaluate the effectiveness of the test products in terms of changes in SCORAD severity scoring,
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 mins on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
Total SCORAD index is 103. Higher scores indicating greater severity. 0-3 description applies only to individual intensity components (0 indicates none, 1 indicates mild intensity, 2 indicates moderate intensity, and 3 indicates severe intensity). Improvement in SCORAD score
To evaluate the effectiveness of the test products in terms of changes in Eczema Area and Severity Index
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
The total maximum score for the EASI is 72. Scoring Scale indicates none (0), mild (1), moderate (2) and severe (3). 0-3 description applies only to individual signs. Improvement in EASI score will be evalauted.
To evaluate the effectiveness of the test products in terms of changes in visual assessment of post inflammatory hyperpigmentation.
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
Scoring scale indicates a 0-4 categorical scale (0: absent, 1: slight, 2: mild, 3: moderate, 4: maximum). Improvement in PIHASI score.

12 secondary outcomes

To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin scaliness
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment including roughness
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin redness
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin itchiness
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin dryness
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in visual and tactile assessment of skin smoothness
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in Visual Analogue Scale for Itching
Time frame: before usage of the test products on Day 01 and after usage of test products at 30 minutes on Day 01, Day 30 (± 2 Days), Day 60 (± 2 Days).
To evaluate the effectiveness of the test products in terms of changes in skin hydration
Time frame: baseline before usage and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness of the test products in terms of changes in skin barrier function
Time frame: before usage and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness of the test products in terms of changes in skin topography
Time frame: before usage and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness impact of the test products in the shift of skin microbiome by collecting skin swab
Time frame: before usage on Day 01 and after usage on Day 30 (±2 Days) and Day 60 (±2 Days)
To evaluate the effectiveness of the test products in terms of changes in product perception questionnaire
Time frame: before usage and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
Individual participant dataSharing planned: No

Related trials for Atopic Dermatitis

Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Dr. Nayan K Patel study director

NovoBliss Research Pvt Ltd

Apeksha Merja principal investigator

NovoBliss Research Pvt Ltd

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Treatment Cream in people with Atopic Dermatitis, run by NovoBliss Research Pvt Ltd at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To evaluate the effectiveness of the test products in terms of change in Dry Skin/Ichthyosis Area and Severity Index (DASI) (time frame: baseline before usage on Day 01 and after usage of the test products at 30 minutes on Day 01, Day 30 (±2 Days) and Day 60 (±2 Days)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06687512.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.